Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.

Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S.

Kidney Int. 2014 Jul;86(1):34-9. doi: 10.1038/ki.2013.528. Review.

PMID:
24402094
2.

Erythropoietin use in CKD patients with cancer: to tread with caution?

Nayak-Rao S, McCormick B.

J Nephrol. 2013 Sep-Oct;26(5):829-35. doi: 10.5301/jn.5000316. Review.

PMID:
24052463
3.

Emerging drugs for treatment of anemia of chronic kidney disease.

Magwood JS, Lebby A, Chen B, Kessler S, Norris L, Bennett CL.

Expert Opin Emerg Drugs. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Review.

PMID:
24033253
4.

Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?

Malyszko J, Glowinska I, Mysliwiec M.

Transplant Proc. 2012 Dec;44(10):3013-6. doi: 10.1016/j.transproceed.2012.06.070.

PMID:
23195016
5.

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF.

Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Review.

PMID:
20439566
6.

New Treatment Approaches for the Anemia of CKD.

Bonomini M, Del Vecchio L, Sirolli V, Locatelli F.

Am J Kidney Dis. 2016 Jan;67(1):133-42. doi: 10.1053/j.ajkd.2015.06.030. Review.

PMID:
26372086
7.

[Erythropoietin stimulating agents in chronic kidney disease: indications and contraindications].

Żebrowski P, Mieczkowski M.

Wiad Lek. 2016;69(5):753-755. Polish.

PMID:
28033602
8.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9.

PMID:
17895328
9.

Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Warady BA, Silverstein DM.

Pediatr Nephrol. 2014 Sep;29(9):1493-505. doi: 10.1007/s00467-013-2557-x. Review.

PMID:
24005791
10.

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.

Del Vecchio L, Locatelli F.

Expert Opin Drug Saf. 2012 Nov;11(6):923-31. doi: 10.1517/14740338.2012.712680. Review.

PMID:
22916722
11.

A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.

Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R.

Eur J Clin Pharmacol. 2013 Apr;69(4):929-36. doi: 10.1007/s00228-012-1412-5.

PMID:
23052412
12.

Erythropoiesis stimulating agents and anaemia of end-stage renal disease.

Schmid H, Schiffl H.

Cardiovasc Hematol Agents Med Chem. 2010 Jul;8(3):164-72. Review.

PMID:
20443766
13.

An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.

Del Vecchio L, Locatelli F.

Expert Opin Drug Saf. 2016 Aug;15(8):1021-30. doi: 10.1080/14740338.2016.1182494. Review.

PMID:
27149639
14.

New strategies for managing anemia of chronic kidney disease.

Schmid H, Schiffl H, Lederer SR.

Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):339-51. Review.

PMID:
22642238
15.

Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.

Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB; ESA Clinic Study Group..

Am J Kidney Dis. 2012 Sep;60(3):371-9. doi: 10.1053/j.ajkd.2012.04.013.

PMID:
22633556
16.

Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.

Locatelli F, Gascón P.

Oncologist. 2009;14 Suppl 1:57-62. doi: 10.1634/theoncologist.2009-S1-57. Review.

17.

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

Robles NR.

Clin Drug Investig. 2016 Jun;36(6):421-31. doi: 10.1007/s40261-016-0378-y. Review.

PMID:
26894799
18.

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

Nowrousian MR, Dunst J, Vaupel P.

Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Review.

PMID:
18330508
19.

[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].

Lovcić V, Vujić J, Ivanac Janković R, Basić-Jukić N, Barisić I, Lovcić P, Dzapo M.

Acta Med Croatica. 2009 Sep;63 Suppl 1:11-6. Croatian.

PMID:
20232547
20.

Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?

Hung SC, Lin YP, Tarng DC.

J Formos Med Assoc. 2014 Jan;113(1):3-10. doi: 10.1016/j.jfma.2013.09.004. Review.

Supplemental Content

Support Center